DDInter1484 DDInter1625
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan
Plicamycin may lead to a major life threatening interaction when taken with Regorafenib